A
66.00
-0.51 (-0.77%)
Penutupan Terdahulu | 66.51 |
Buka | 64.90 |
Jumlah Dagangan | 499,973 |
Purata Dagangan (3B) | 757,876 |
Modal Pasaran | 3,637,042,176 |
Harga / Jualan (P/S) | 44.70 |
Harga / Buku (P/B) | 8.37 |
Julat 52 Minggu | |
Tarikh Pendapatan | 19 Aug 2025 - 3 Sep 2025 |
Margin Keuntungan | -211.46% |
Margin Operasi (TTM) | -847.56% |
EPS Cair (TTM) | -2.99 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -79.30% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 12.76% |
Nisbah Semasa (MRQ) | 4.93 |
Aliran Tunai Operasi (OCF TTM) | -114.70 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.43 M |
Pulangan Atas Aset (ROA TTM) | -16.69% |
Pulangan Atas Ekuiti (ROE TTM) | -35.56% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Arcellx, Inc. | Menurun | Menaik |
AISkor Stockmoo
2.3
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | 0.5 |
Purata | 2.25 |
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 14.50% |
% Dimiliki oleh Institusi | 102.08% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 115.00 (HC Wainwright & Co., 74.24%) | Beli |
Median | 110.00 (66.67%) | |
Rendah | 93.00 (Scotiabank, 40.91%) | Beli |
Purata | 106.00 (60.61%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 61.51 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Citigroup | 17 Jun 2025 | 110.00 (66.67%) | Beli | 62.88 |
HC Wainwright & Co. | 16 Jun 2025 | 115.00 (74.24%) | Beli | 64.09 |
Scotiabank | 09 May 2025 | 93.00 (40.91%) | Beli | 57.55 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
21 May 2025 | Pengumuman | Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 |
14 May 2025 | Pengumuman | Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma |
08 May 2025 | Pengumuman | Arcellx Provides First Quarter 2025 Financial Results and Business Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |